Navigation Links
NeoStem's CEO Letter to Shareholders
Date:1/3/2012

NEW YORK, Jan. 3, 2012 /PRNewswire/ --

Dear NeoStem Shareholders,

We would like to take a moment to both look back at 2011 - a transformative year for NeoStem (NYSE Amex: NBS) – and to look ahead to near term catalysts that we expect to move the company forward in 2012 and beyond.

  • We have closed two acquisitions - Progenitor Cell Therapy, LLC ("PCT") and Amorcyte, LLC ("Amorcyte").
  • We believe our therapeutic product development team is very close to accomplishing its aggressive goal of getting a first patient enrolled in our AMR-001 Phase 2 clinical trial for the treatment of AMI with the clinical sites beginning to open.  This brings us closer to achieving our goal of enrollment of the targeted 160 patients in the study over the next year or so with first data follow-up six months after the last patient is enrolled (roughly mid-2013).
  • Our cell therapy manufacturing business is growing and client satisfaction confirms our belief and excitement that we have unique skills and people (expertise, quality and work ethic) to serve as a platform to be a global leader in the cell therapy space.
  • We raised $16.5 million in gross proceeds in 2011 for working capital, including research and development of our cell therapeutic candidates.
  • We received awards of over $1.7 million in Department of Defense funding for development of our VSELTM Technology to treat osteoporosis and $245,176 from the National Institutes of Health (NIH) with Excell Therapeutics to progress our T regulatory program in Lupus. 
  • We co-hosted a spectacular international conference in partnership with the Vatican's Pontifical Council for Culture on Adult Stem Cells: Science and the Future of Man and Culture, moving forward the public discussion of adult stem cells and adult stem cell research.
  • Our cord blood banking
    '/>"/>

  • SOURCE NeoStem, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related biology technology :

    1. Huifeng Bio-Pharmaceutical (HFGB) Enters into Letter of Intent with Xian Qinba Xintong Medical Ltd.
    2. CTI Receives NASDAQ Letter
    3. Synvista Therapeutics Posts Letter to Stockholders on Web Site
    4. Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards
    5. Letter to Shareholders from the CEO and Chairman of the Board of Yongye Biotechnology, Inc.
    6. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
    7. Vical and AnGes MG Sign Letter of Intent for Pandemic Influenza Program
    8. Cell Therapeutics to Request a Hearing With NASDAQ Following Receipt of Staff Determination Letter
    9. Spherix Receives Nasdaq Letter Extending Minimum Bid Price Compliance Period
    10. Caraco Pharmaceutical Laboratories, Ltd. Receives FDA Warning Letter
    11. deCODE Requests Hearing With Nasdaq Following Receipt of Staff Determination Letter
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/26/2014)... , Nov. 26, 2014 The ... from a survey of European physicians at the ... Innovation and Biological Therapies" at the Spanish Ministry ... hosted by EuropaBio and the Spanish Bioindustry Association ... Health, physicians from Spanish oncology and rheumatology societies, ...
    (Date:11/26/2014)... November 25, 2014 SonaCare Medical, ... Ultrasound (HIFU) devices, recently participated in the American ... Mass 360° .” Key opinion leaders in urology ... related to small renal masses while attendees had ... ablative technologies in hands-on labs. Attendees at the ...
    (Date:11/26/2014)... Miles Holder, formerly of Micron Research ... Products team as Sales/Marketing Manager. Mr. Holder has over ... for the graphite industry. , “We are thrilled to ... Dave Trinkley, VP of Market and Product Development for ... in the graphite industry, along with his proven track ...
    (Date:11/26/2014)... -- Bio-Techne Corporation (NASDAQ: TECH ) announced ... to serve in a newly created position of Senior ... will be responsible for managing the operations of Bio-Techne,s ... acquired in July 2014 and the recently acquired CyVek ... -based ProteinSimple develops and commercializes proprietary systems and consumables ...
    Breaking Biology Technology:ASBM Presents European Physicians Survey at Spanish Ministry of Health 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3
    ... Calif., Dec. 5, 2011 OvaGene Oncology Inc., ... and commercialization of personalized gene-based diagnostics for gynecologic ... major Licensing and Collaboration Agreement with The Moffitt ... Comprehensive Cancer Center in Florida.  The agreement provides ...
    ... REDWOOD CITY, Calif., Dec. 5, 2011 Codexis, Inc. (Nasdaq: ... has been named Vice President and Chief Marketing Officer.  ... for the company,s corporate marketing and communications.  He will ... Officer. Mr. Bolsen is a widely recognized ...
    ... 2011  Immune Design Corp. announced today that Wayne ... new Chief Development Officer.  Dr. Gombotz brings a ... key leadership position at Immune Design.  He will ... therapeutic vaccine product candidates. (Logo: ...
    Cached Biology Technology:OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response 2OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response 3Codexis Names Wes Bolsen VP and Chief Marketing Officer 2Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer 2
    (Date:11/21/2014)... , Nov. 20, 2014 Strict laws ... efficiency are piloting the North American and European automotive ... accidents growing, gesture recognition systems that are intuitive and ... mark in the industry. New analysis ... Gesture Recognition Market in Europe ...
    (Date:11/18/2014)... 2014 The Parenteral Drug Association (PDA) today confirmed ... speak and at least seven more will participate in the ... Shoreham Hotel in Washington D.C. , Dec. ... significant support from the regulatory agencies in the ... in our effort to help advance the use of metrics ...
    (Date:11/10/2014)... Laundry detergent pods began appearing on U.S. store shelves ... growing numbers ever since. The small packets can be ... measure out a liquid or powder. The convenience, though, ... new study from researchers at Nationwide Children,s Hospital found ... received reports of 17,230 children younger than 6 years ...
    Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Study finds laundry detergent pods, serious poisoning risk for children 2
    ... delivers new insight about rapid toxin evolution in venomous snakes: ... race with opossums, a group of snake-eating American marsupials. Although ... this fact has not been factored into previous explanations for ... usually seen as a feeding, or trophic, adaptation. But new ...
    ... contrast agents that sneak into bacteria disguised as glucose ... sensitivity and specificity. These agents -- called maltodextrin-based imaging ... other inflammatory conditions. "These contrast agents fill the ... of bacteria in vivo and distinguish infections from other ...
    ... 18, 2011) Researchers from the John Theurer Cancer ... 14 cancer-related studies during the recently concluded American Society ... June 3 7, 2011 in Chicago. The studies ... treatment outcomes, and patient quality of life issues. ...
    Cached Biology News:Rapid venom evolution in pit vipers may be defensive 2Rapid venom evolution in pit vipers may be defensive 3New contrast agents detect bacterial infections with high sensitivity and specificity 2New contrast agents detect bacterial infections with high sensitivity and specificity 3John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 2John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 3John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 4John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 5John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 6